Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyBluecross Idaho Gazyva Coverage Prior Auth | OpenP…
    Ask Trek AI about this page
    ModifiedBluecross IdahoPolicy 5.01.501

    Gazyva (obinutuzumab) for Non-oncologic Uses

    Customize your policy alerts

    Sign up for Bluecross Idaho Policy 5.01.501 alerts

    Get alerted when Policy 5.01.501 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines medical benefit coverage and prior authorization criteria for intravenous obinutuzumab when used for non-oncologic indications, primarily for treatment of active lupus nephritis in adults; applies to Bluecross Idaho members subject to their specific benefit plans.

    Policy Summary
    PayerBluecross Idaho
    PolicyGazyva (obinutuzumab) for Non-oncologic Uses
    Policy CodePolicy 5.01.501
    Change TypeNew policy added
    Effective DateJun 1, 2026
    Last ReviewFeb 26, 2026
    Next Review DateFeb 26, 2026
    Key ActionSubmit prior authorization with diagnosis coding and required clinical documentation to request IV Gazyva for active lupus nephritis.
    SourceLink
    POLICY UPDATE CHANGES

    New policy added to prescription drug section for Gazyva for treatment of active lupus nephritis in those with systemic lupus erythematosus.

    1Main indication
    18+Min age
    <0.5 g/gProteinuria threshold
    ≥80%eGFR threshold

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1HCPCS codes listed
    3References

    Coverage Criteria for Gazyva (obinutuzumab)

    inv-01: Initial Therapy

    Covered when ALL of the following are met:

    Initial Treatment: Individual is 18 years of age or older
    SLE diagnosis: Diagnosis of systemic lupus erythematosus (SLE) according to American College of Rheumatology classification criteria
    Biopsy-proven LN class: Biopsy-proven active lupus nephritis Class III or IV, with or without Class V
    Autoantibody positivity: Individual is autoantibody positive with ONE of: (a) ANA above laboratory reference range OR (b) anti-dsDNA above laboratory reference range or >2x reference if tested by ELISA
    Concomitant therapy: Will receive Gazyva in combination with a standard immunosuppressive therapy regimen for active LN (e.g., azathioprine, cyclophosphamide, glucocorticoids, mycophenolic acid analogs)
    No other biologic or targeted immunomodulator: Requested agent is NOT being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator
    Prescriber specialty: The prescriber is a specialist in the area of the patient's diagnosis (e.g., rheumatologist, nephrologist)

    inv-02: Continuation Therapy

    Continuation requests are covered when ALL of the following are met:

    Prior approval met: Coverage criteria for initiation of Gazyva (obinutuzumab) therapy for the requested indication has previously been met
    Ongoing standard LN therapy: Individual is currently being treated with and will continue receiving standard immunosuppressive LN therapy (e.g., azathioprine, cyclophosphamide, glucocorticoids, mycophenolic acid analogs)
    No concomitant biologics: Requested agent is NOT being used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator
    Prescriber specialty: The prescriber is a specialist in the area of the patient's diagnosis (e.g., rheumatologist, nephrologist)

    inv-03: Initial and Continuing Therapy (summary)

    Policy includes coverage criteria for initial and continuing treatment of active lupus nephritis with Gazyva as adopted by Blue Cross of Idaho.

    Policy adoption: New policy for Gazyva for treatment of active lupus nephritis in those with systemic lupus erythematosus; includes initial and continuing treatment criteria (criteria details in policy sections).

    See main policy sections for full criteria text.

    IV obinutuzumab is considered investigational for all non-oncologic indications other than the specific indications addressed in this policy (see criteria for active lupus nephritis).

    Inclusion of a billing or diagnostic code in the policy materials does not guarantee coverage. Coverage determinations are subject to the member-specific benefit plan documentation and the terms and conditions of the applicable plan, as well as any other applicable policies or legal requirements.

    Use of intravenous obinutuzumab (Gazyva) for non-oncologic indications other than active lupus nephritis is considered investigational and is not covered under this policy.

    Within this document segment there are no explicit statements labeled as 'not medically necessary.'

    Coding and Clinical Thresholds

    Coding table referencedmixed
    No codes listed
    Covered HCPCS Codes (reference)HCPCS
    J9301Injection, obinutuzumab, 10 mg (Gazyva)
    Relevant ICD-10-CM Diagnosis CodesICD-10
    M32.0 - M32.9Systemic lupus erythematosus (SLE)
    inv-11: Urine protein:creatinine ratio (UPCR) — threshold for complete renal response.
    Complete renal response - proteinuriaUrine protein:creatinine ratio (UPCR) < 0.5 g/g
    ContextRequired as one component of 'complete renal response' for continuation of Gazyva in active lupus nephritis
    MeasurementUPCR reported in g/g (spot urine) as specified in continuation criteria
    inv-12: Estimated glomerular filtration rate (eGFR) change from baseline — at least 80% of baseline (no decrease >20%).
    eGFR stabilization thresholdEstimated glomerular filtration rate (eGFR) at least 80% of baseline (no decrease >20% from baseline)
    Context

    Provider Actions, Documentation, and Authorization

    Prior Authorization

    Prior authorization required for non‑oncologic Gazyva

    Prior authorization is required for intravenous Gazyva (obinutuzumab) when requested for non-oncologic indications and will be evaluated against the policy's initiation and continuation criteria. Oncologic uses are evaluated per NCCN and oncology policy guidance.

    Prior Authorization

    Authorization required — submit diagnosis and drug codes

    This is a new prescription drug policy for Gazyva for treatment of active lupus nephritis; submit the appropriate diagnosis coding (ICD‑10 M32.0‑M32.9) and the HCPCS code for obinutuzumab (J9301) when requesting authorization.

    Step Therapy

    Combination therapy required; concomitant biologics prohibited

    Key Definitions

    inv-22: Biopsy-proven active lupus nephritis — Active lupus nephritis Classes III or IV (with or without Class V).
    DefinitionBiopsy-proven active lupus nephritis: Classes III or IV (with or without Class V)
    SourceRequired documentation includes kidney biopsy class showing active Class III/IV (with or without Class V)
    Use in criteriaOne of the required elements for initiation of Gazyva for active lupus nephritis
    inv-23: Autoantibody positive — Defined as ANA above lab reference range OR anti-dsDNA above lab reference range or >2x reference if ELISA.
    Autoantibody positivity criteriaANA above the laboratory reference range OR anti-dsDNA above the laboratory reference range, or >2x reference if tested by ELISA
    Role in initiationAt least one of these autoantibody results is required for initiation of therapy

    Background

    Obinutuzumab (Gazyva) is an anti-CD20 monoclonal antibody that depletes B cells through multiple mechanisms, including immune effector functions, induction of direct cell death, and complement-dependent cytotoxicity. It is FDA-approved for certain hematologic malignancies and, per this policy, is addressed for use in combination with standard immunosuppressive therapy for treatment of active lupus nephritis.

    Policy Revision History

    2026-02-26policy_adoptionLatest

    Blue Cross of Idaho adopted a new prescription drug policy for Gazyva (obinutuzumab) for treatment of active lupus nephritis; policy to be effective 2026-06-01 and includes initial and continuing treatment criteria.

    Policy Summary
    PayerBluecross Idaho
    PolicyGazyva (obinutuzumab) for Non-oncologic Uses
    Policy CodePolicy 5.01.501
    Change TypeNew policy added
    Effective DateJun 1, 2026
    Last ReviewFeb 26, 2026
    Next Review DateFeb 26, 2026
    Key ActionSubmit prior authorization with diagnosis coding and required clinical documentation to request IV Gazyva for active lupus nephritis.
    SourceLink
    On This Page
    Coverage Criteria for Gazyva (obinutuzumab)Coding and Clinical ThresholdsProvider Actions, Documentation, and AuthorizationKey DefinitionsBackgroundPolicy Revision History
    Complete renal response: Individual has achieved a complete renal response as indicated by BOTH: (1) reduction in proteinuria (UPCR < 0.5 g/g) AND (2) stabilization or improvement in kidney function (eGFR at least 80% of baseline [no decrease in eGFR more than 20% from baseline])
    Required as the kidney function component of 'complete renal response' for continuation of Gazyva
    DirectionRepresents stabilization or improvement compared with baseline eGFR

    Gazyva must be administered in combination with a standard immunosuppressive therapy regimen for active lupus nephritis and must not be used in combination with any other biologic DMARD, targeted synthetic DMARD, or other immunomodulator.

    Note

    Example concomitant and prior DMARDs (lists provided)

    The policy provides example lists of conventional, biologic, and targeted synthetic DMARDs to reference when documenting concomitant therapies or prior treatments.

    • Conventional DMARD examples: azathioprine, cyclophosphamide, cyclosporine, hydroxychloroquine, leflunomide, methotrexate, mycophenolate, sulfasalazine
    • Biologic DMARD examples: abatacept, adalimumab, anakinra, infliximab, rituximab, etc.
    • Targeted synthetic DMARD examples: apremilast, baricitinib, deucravacitinib, tofacitinib, upadacitinib
    Documentation Required

    Clinical documentation required for authorization

    Required clinical documentation for authorization requests must include the patient's age, SLE diagnosis per American College of Rheumatology criteria, and kidney biopsy demonstrating active lupus nephritis Class III or IV (with or without Class V); also include autoantibody results, current immunosuppressive regimen, and prescriber specialty.

    • Autoantibody documentation: ANA above laboratory reference range OR anti‑dsDNA above reference range (or >2× reference if ELISA)
    • Prescriber specialty: rheumatologist or nephrologist, as appropriate
    • Current standard immunosuppressive LN therapy (e.g., azathioprine, cyclophosphamide, glucocorticoids, mycophenolic acid analogs)
    Billing Rule

    Coding guidance — use M32.x and J9301

    When submitting authorization requests, document the diagnosis of systemic lupus erythematosus using ICD‑10 codes M32.0–M32.9 and include the applicable HCPCS code for obinutuzumab (J9301) as coding guidance.

    Denial Risk

    Denial triggers — criteria not met or investigational uses

    Requests that do not meet the medical necessity criteria for active lupus nephritis (either initiation or continuation criteria) or requests for other non‑oncologic uses of IV obinutuzumab may be denied.

    • IV obinutuzumab is considered investigational for all other non‑oncologic indications
    Note

    Coverage determinations subject to member benefit plan

    Coverage determinations are subject to the member's specific benefit plan documentation and additional terms and conditions; inclusion of a code in this policy does not guarantee coverage or payment.

    DocumentationLaboratory results must be provided showing ANA or anti-dsDNA per the specified thresholds
    inv-24: M32.0 - M32.9 — Systemic lupus erythematosus (SLE) ICD-10 range.
    ICD-10 rangeM32.0 - M32.9
    DescriptionSystemic lupus erythematosus (SLE)
    Coding guidanceDocument diagnosis of SLE (M32.x) when requesting obinutuzumab per policy coding guidance